FBR just downgraded its rating for Disney and Time Warner to market perform from outperform. » Read More
The Dow hit a record high Tuesday, and one strategist believes the index will rally to 20,000 by year-end.
Tokyo-based chat app Line launched in 2011, following a catastrophic earthquake and tsunami in Japan. Now it's about to go public.
After taking a big dive to start the year, consumer banks outpaced Wall Street I-banks’ shares in recovering.
MKM Partners derivatives strategist Jim Strugger gives his best earnings-trade ideas in a note to clients.
Pandora Media shares popped nearly 3 percent following Piper Jaffray's upgrading the company to "overweight" from "neutral."
A record price reached by the S&P 500 this week cleared the way for further gains ahead, Bank of America Merrill Lynch told clients.
Jim Cramer says youth are doing things with technology he can’t understand, and it’s time to change to adapt to the new landscape
The "Fast Money" traders share their first moves for Wednesday.
Some of the names on the move ahead of the open.
Jim Cramer goes off the charts to look at one group that has the power to fuel the averages even further than imagined.
Jim Cramer saw eye popping signals that the global economy could be doing better than investors realize.
Shares of Seagate Technology swelled 22% after the company announced a restructuring plan that includes 6,500 job cuts.
Shares of Oracle rose 1.6 percent on Tuesday after an analyst was optimistic on Oracle's cloud growth.
One of the best performing stocks in the S&P 500 is a little-followed company that deals with technology-related real estate.
The S&P 500 roared back from a post-Brexit sell-off to set a new all-time record high, but David Alton Clark believes this is unjustified.
Goldman Sachs chief U.S. equity strategist David Kostin is expecting a pullback and a range-bound market for the next two years.
United Continental shares soared more than 6 percent on Tuesday after the airline company announced positive guidance.
Shares of Shire rose more than 3 percent after it won approval from the FDA for its new dry-eye treatment Xiidra.
Shares of CytRx took a huge hit after the company missed the mark in Phase 3 trial of its new cancer drug.
The ETF industry has come a long way in 23 years, and indications are that it's only going to get bigger — a lot bigger.
Get the best of CNBC in your inbox